First Berlin Equity Research publishes independent analysis of Cyxone
Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.
The independent analysis covers the first quarter of 2020 and was published on 26 June 2020, where First Berlin reviewed the company’s potential with an expected but continued positive outcome.
The report in English can be read in its entirety on the Cyxone’s website.
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
This contains such information that Cyxone AB is required to make public under the EU’s Market Abuse Regulation. The information was provided under the auspices of the above contact person for publication on 26 June 2020 at 14.25 CET.
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, firstname.lastname@example.org. www.cyxone.com